Comparison of two inhibitors of E-type prostanoid receptor four and carprofen in dogs with experimentally induced acute synovitis

Steven C. Budsberg 1Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Steven C. Budsberg in
Current site
Google Scholar
PubMed Close
 DVM, MS
,
Stephanie A. Kleine 1Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Stephanie A. Kleine in
Current site
Google Scholar
PubMed Close
 DVM, PhD
,
Megan M. Norton 1Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Megan M. Norton in
Current site
Google Scholar
PubMed Close
 MS
, and
Gabriella S. Sandberg 1Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Gabriella S. Sandberg in
Current site
Google Scholar
PubMed Close
 BS
DOI:
https://doi.org/10.2460/ajvr.80.11.1001
Volume/Issue:
Volume 80: Issue 11
Online Publication Date:
01 Nov 2019
Restricted access
Sign In Reprints and Permissions Purchase Article

Abstract

OBJECTIVE

To investigate the ability of a proprietary antagonist of E-type prostanoid receptor (EP) 4, grapiprant, and carprofen to attenuate lameness attributable to urate-induced synovitis in dogs.

ANIMALS

5 purpose-bred hound-cross dogs.

PROCEDURES

A blinded, 3-way crossover study was performed. Dogs received each of 3 treatments (L-766, a proprietary antagonist of EP4; 4.0 mg/kg), grapiprant (an antagonist of EP4; 2.0 mg/kg), and carprofen (4.4 mg/kg); dogs received 4 doses of each treatment (14 and 2 hours before and 22 and 46 hours after urate injection). Synovitis was induced by intra-articular injection of sodium urate. Measurements (vertical ground reaction forces and clinical lameness scores) were obtained immediately before (0 hours; baseline) and 6, 12, 24, 36, and 48 hours after sodium urate injection. All data were analyzed with repeated-measures ANOVA.

RESULTS

Lameness scores at 6 hours were significantly higher than baseline lameness scores for all treatments. Lameness scores for the grapiprant treatment remained significantly higher at 12 and 24 hours, compared with baseline lameness scores. Lameness scores for the carprofen treatment were significantly lower than lameness scores for the grapiprant treatment at 6, 12, and 24 hours. Analysis of peak vertical force and vertical impulse data revealed a pattern similar to that for lameness scores. Treatment with L-766 resulted in a significantly higher vertical impulse at 48 hours than did treatment with carprofen or grapiprant.

CONCLUSIONS AND CLINICAL RELEVANCE

In these dogs, carprofen was the most effective treatment for attenuating lameness induced by injection of sodium urate, and grapiprant was the least effective treatment.

Abstract

OBJECTIVE

To investigate the ability of a proprietary antagonist of E-type prostanoid receptor (EP) 4, grapiprant, and carprofen to attenuate lameness attributable to urate-induced synovitis in dogs.

ANIMALS

5 purpose-bred hound-cross dogs.

PROCEDURES

A blinded, 3-way crossover study was performed. Dogs received each of 3 treatments (L-766, a proprietary antagonist of EP4; 4.0 mg/kg), grapiprant (an antagonist of EP4; 2.0 mg/kg), and carprofen (4.4 mg/kg); dogs received 4 doses of each treatment (14 and 2 hours before and 22 and 46 hours after urate injection). Synovitis was induced by intra-articular injection of sodium urate. Measurements (vertical ground reaction forces and clinical lameness scores) were obtained immediately before (0 hours; baseline) and 6, 12, 24, 36, and 48 hours after sodium urate injection. All data were analyzed with repeated-measures ANOVA.

RESULTS

Lameness scores at 6 hours were significantly higher than baseline lameness scores for all treatments. Lameness scores for the grapiprant treatment remained significantly higher at 12 and 24 hours, compared with baseline lameness scores. Lameness scores for the carprofen treatment were significantly lower than lameness scores for the grapiprant treatment at 6, 12, and 24 hours. Analysis of peak vertical force and vertical impulse data revealed a pattern similar to that for lameness scores. Treatment with L-766 resulted in a significantly higher vertical impulse at 48 hours than did treatment with carprofen or grapiprant.

CONCLUSIONS AND CLINICAL RELEVANCE

In these dogs, carprofen was the most effective treatment for attenuating lameness induced by injection of sodium urate, and grapiprant was the least effective treatment.

Contributor Notes

Address correspondence to Dr. Budsberg (Budsberg@uga.edu).
Cover American Journal of Veterinary Research
American Journal of Veterinary Research
Publication Date:
01 Nov 2019

  • 1. Budsberg SC. Nonsteroidal anti-inflammatory drugs. In: Gaynor JS, Muir WW, eds. Handbook of veterinary pain management. 3rd ed. St Louis: Mosby, 2014;142–160.

    • Search Google Scholar
    • Export Citation

  • 2. Konya V, Marsche G, Schuligoi R, et al. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 2013;138:485–502.

  • 3. Tang EH, Libby P, Vanhoutte PM, et al. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol 2012;59:116–123.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 4. Ota H, Katanosaka K, Murase S, et al. EP2 receptor plays pivotal roles in generating mechanical hyperalgesia after lengthening contractions. Scand J Med Sci Sports 2018;28:826–833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 5. Chandrasekhar S, Yu XP, Harvey AK, et al. Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists. Pharmacol Res Perspect 2017;5:e00316.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 6. Rausch-Derra L, Huebner M, Wofford J, et al. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med 2016;30:756–763.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 7. Punke JP, Speas AL, Reynolds LR, et al. Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis. Am J Vet Res 2007;68:704–708.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 8. Cross AR, Budsberg SC, Keefe TJ. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am J Vet Res 1997;58:626–631.

    • Search Google Scholar
    • Export Citation

  • 9. Cathcart CJ, Johnston SA, Reynolds LR, et al. Efficacy of ABT-116, a TRPV1 antagonist, in providing analgesia for dogs with chemically induced synovitis. Am J Vet Res 2012;73:19–26.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 10. Budsberg SC, Torres BT, Zwijnenberg RJ, et al. Effect of perzinfotel and a proprietary A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis. Am J Vet Res 2011;72:757–763.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 11. Drag M, Kunkle BN, Romano D, et al. Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. Vet Ther 2007;8:41–50.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 12. Hazewinkel HA, van den Brom WE, Theyse LF, et al. Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. Res Vet Sci 2008;84:74–79.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 13. Millis DL, Weigel JP, Moyers T, et al. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther 2002;3:453–464.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 14. Borer LR, Peel JE, Seewald W, et al. Effect of carprofen, etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis. Am J Vet Res 2003;64:1429–1437.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 15. Borer LR, Seewald W, Peel JE, et al. Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. J Vet Pharmacol Ther 2017;40:148–157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 16. Clark P, Rowland SE, Denis D, et al. MF498 [N–{[4–(5,9–Diethoxy–6–oxo–6,8–dihydro–7H–pyrrolo[3,4–g]quinolin–7–yl)–3–methylbenzyl]sulfonyl}–2–(2–methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 2008;325:425–434.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 17. Chen Q, Muramoto K, Masaaki N, et al. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol 2010;160:292–310.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 18. Honda T, Segi-Nishida E, Miyachi Y, et al. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 2006;203:325–335.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 19. Xu D, Rowland SE, Clark P, et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008;326:754–763.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 20. Nakao K, Murase A, Ohshiro H, et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2007;322:686–694.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 21. Nagahisa A, Okumura T. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. J Vet Pharmacol Ther 2017;40:285–292.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 22. Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophysic Acta 2015;1851:414–421.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 23. Zeilhofer HU, Brune K. Analgesic strategies beyond the inhibition of cycooxygenases. Trends Pharmacol Sci 2006;27:467–474.

  • 24. Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci 2013;34:413–423.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 25. Harvey RJ, Depner UB, Wassle H, et al. GlyR α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 2004;304:884–887.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 26. Kunori S, Matsumura S, Okuda-Ashitaka E, et al. A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord. Glia 2011;59:208–218.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 27. Autefage A, Palissier FM, Asimus E, et al. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec 2011;168:617.

  • 28. Budsberg SC, Johnston SA, Schwarz PD, et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999;214:206–210.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 29. Doig PA, Purbrick KA, Hare JE, et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000;41:296–300.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 30. Pollmeier M, Toulemonde C, Fleishman C, et al. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec 2006;159:547–551.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 31. Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995;206:807–811.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 32. Reymond N, Speranza C, Gruet P, et al. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J Vet Pharmacol Ther 2012;35:175–183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 33. Kondo Y, Takashima K, Matsumoto S, et al. Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan. J Vet Med Sci 2012;74:1283–1289.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 34. Friton G, Thompson CM, Karadzoyska D, et al. Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs. BMC Vet Res 2017;13:197–209.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 35. Gruet P, Seewald S, King JN. Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial. BMC Vet Res 2013;9:92–104.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 36. Caulkett N, Read M, Fowler D, et al. A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs. Can Vet J 2003;44:565–570.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 37. Karrasch NM, Lerche P, Aarnes TK, et al. The effects of pre-operative oral administration of carprofen or tramadol on postoperative analgesia in dogs undergoing cutaneous tumor removal. Can Vet J 2015;56:817–822.

    • PubMed
    • Search Google Scholar
    • Export Citation

  • 38. Delgado C, Bentley E, Hetzel S, et al. Comparison of carprofen and tramadol for postoperative analgesia in dogs undergoing enucleation. J Am Vet Med Assoc 2014;245:1375–1381.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

  • 39. Lascelles BD, Cripps PJ, Jones A, et al. Efficacy and kinetics of carprofen, administered preoperatively or postoperatively, for the prevention of pain in dogs undergoing ovariohysterectomy. Vet Surg 1998;27:568–582.

    • Crossref
    • Search Google Scholar
    • Export Citation

  • 40. Bienhoff SE, Smith ES, Roycroft LM, et al. Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg 2012;41:336–344.

    • PubMed
    • Search Google Scholar
    • Export Citation

Advertisement